 Nile DeManna is the CEO of Manna Molecular. And one of the cool things I learned about this company recently is that within Manna is another company called Vella. And it has a lot to do with products geared towards women and in particular women and their sexuality. And I'm going to turn it over to Nile because now you were telling me about some of the research that Manna had done. And that's really kind of what sets Manna Molecular apart, in my opinion, is that this is a company that really heavily focuses on the science and they let the science take them wherever that goes. Tell me how Vella came about. Yeah, sure. So Vella came about. We were looking for a second product. We did patches first. And that's a very niche product, very high barrier to entry and requires specialized knowledge. And we liked that method. And we wanted to apply it to whatever our second product would be. And I had the good fortune of being asked to sponsor an event in LA. And I said yes. And they had the former head of the FDA, David Kessler, there. And the host was this doctor, Dr. Herron Padman-Nathan. And as he was recruiting me for an investment, just to sponsor his event, I got to talking with him and really liked him and just said, hey, you've had a really amazing background. What do you think about cannabinoids in women and sex? And he was kind of interested in it. And the more I talked to him, the more I convinced him that this would be a good idea. And I eventually ended up recruiting him to the company. And we agreed to follow the same development pathway of Viagra and Cialis, two drugs that he was the principal investigator for. And lo and behold, we found in an organ bath study that there is a dose-response relationship to CBD and smooth muscle tissue relaxation in the vagina. And from there, we got really excited because that's the same pathway that all these other drugs work for. And we went on to test it in 30 women at a 90% success rate across four orgasm outcome measures and a 60% success rate across two arousal measures. And this is a clinically validated instrument, which we modified for our purpose. And then we tested it in a population of women that were taking different antidepressants. And we found out that 100% of them were able to orgasm after they were not able to orgasm since going on their drugs. So all of those things combined made us really excited to move forward. And one really cool thing that we're going to do more of is this photoplethysmography study where you look at temperature and electrical response using probes. And this is from Nicole Prousey's lab. So she's featured in a lot of articles. And we have a relationship with her. So we got an N of 1 on that. And that was very positive, too. So through every indicator we took, we tried to disprove it. And we just kept getting better and better responses. And so this is a topical product, correct? Yeah, so we're calling it a women's pleasure serum. And it's a topical pre-placed serum for arousal orgasm. So the idea is you put it on 20 or so minutes before you have any sexual activity. And it causes relaxation down there. And that allows enhanced sensation and engorgement. And these are hallmarks of good sexual experience. For maybe our readers that aren't as familiar with manumolecular, could you maybe talk a little bit about the company and the other products? Because I know them. But I just don't think maybe our readers are as familiar with your company. Sure. Well, I think that will change pretty soon. We're in about 12 markets. We do some white labeling, although we're really moving towards a strictly brand play, because we've gotten the recognition that we've gotten. But we make transformal patches. And we developed a method where our business licensees and people that are state licensed can basically kit our patches, take their extract, and apply it at the point of production, and create a very high quality repeatable product that's the same across every state. So while in California, we are selling patches under Papon Barkley's name. In a state like Ohio, we're under our own name. And that's more common than not. So in about nine of the 12, we're under our own name. We've got about three white labels. And right now, in fact, we've just released a speed tab, which is a sublingual tablet that, you know, onset is very quick. And we think of it as an ultra-fast edible. And we think that that category, you know, people, these units of gummies, you know, they're a great package for this. But I think it's a fast tablet that tastes good. And that's another thing we wanted to do is we're using naturally extracted terpenes and adding really cool flavors and effects to these. So there's something that you can use during the daytime to focus. We're making a CBN version, which we've gotten really, really good feedback on that to help people fall asleep. And I know COVID has really messed with people's sleep patterns. And we also have a CBD version. And we'll be making different ratios because it's a fast acting tablet. And it lasts for about 60 to 90 minutes. So you can use it to get high. You can use it to treat your pain or inflammation with CBD. Or you can use it to go to bed with CBN. And that's something that I've been using really recently. And it's certainly nice to have in your toolkit. Well, I really like the idea about the fast onset because that's always been the real tricky thing with edibles for people. You don't know whether it's going to take an effect in a half hour or an hour. It's really hard to plan around that. In the offset too, not to interrupt. But it's the offset to me has always been the most important because, hey, I want my experience. But I don't necessarily want to, I've got to go somewhere in three hours or four hours. And I think everybody right now is, they've got multiple Zoom calls. You're at home. Everybody knows that you're at home. So they're more likely to call you at night or at odd hours because you've got nowhere. You're not going to be out. And so I think having something that can fit into somebody's schedule really nicely, you can watch your favorite TV show. And by the time the show's over, the effect's over. So that's kind of how we thought about it, is that there's these really discrete periods of time when you'd like to be able to switch it on and switch it off. And for people that don't like vaping, and given all the vape-related injuries we've been seeing lately, that's not going to go away. And hailables are a big part of the cannabis market. And we understand that. But I do think that people are looking for different methodologies. And there has been an incredible shift towards edibles in this year specifically. And we think that there is room to play in that space. We feel like we're trending up. And our investors feel the same way too. But we certainly welcome other people and other perspectives and other investors. We'd like to get bigger as a company. We'd like to do more deals with the MSOs that we have and expand into states with players that we already work with. So all of those things require capital and operational overhead. But I think we've got the platform technologies to expand, to add new terpenes, new experiences in our patches, and our speed tabs. And we have a beverage powder coming out in about three months too. And again, I think we're really more recreational focused than we were before. And ideally, consumers will really benefit from that. Well, thank you so much for spending your time with us at Green Market Report. I was super excited when I heard all this stuff about Vella. And I really wanted to bring that to our readers' attention and our viewers on our YouTube channel. So if you haven't already, subscribe to our channel now. It's free. And now, thank you so much for joining us. And we're going to keep our eye on man and molecular. I appreciate it. And you're one of my favorite interviewees. So thank you and appreciate the time.